Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRV-101 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PRV-101 | BIOLOGICAL | Coxsackie Virus B vaccine |
| Placebo | OTHER | Placebo |
PRV-101 is a monoclonal antibody being developed for the treatment of viral infections caused by Coxsackie virus. It is currently in Phase 1 clinical development for this infectious disease indication.
PRV-101 is a monoclonal antibody designed to target Coxsackie virus, a viral pathogen responsible for infections. As a monoclonal antibody, it works by binding to the virus to neutralize its activity.
PRV-101 is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker symbol SNY. The drug is currently in Phase 1 clinical development.
PRV-101 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy.
PRV-101 has one completed Phase 1 clinical trial, identified as NCT04690426, titled 'PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers'. This trial enrolled 32 participants and was an uncontrolled, non-randomized study.
PRV-101 is a monoclonal antibody, not a vaccine. While the clinical trial title references a vaccine protocol, the drug itself is classified as a monoclonal antibody for treating Coxsackie virus infections.